A Study of the Next-generation Probiotic, Veillonella Atypica FB0054 vs Placebo

Launched by FITBIOMICS, INC. · Nov 15, 2023

Keywords

ClinConnect Summary

Veillonella is a novel probiotic that can metabolize lactic acid into propionate, which is an energy source for the body. In previous research, the investigators have shown that Veillonella can improve endurance compared to placebo. In mouse studies, those mice who supplemented with V. atypica ran 13% longer in a run-to-exhaustion test than those mice who were given placebo. Furthermore, in a randomized controlled crossover pilot study, the investigators could show that Veillonella prevented 78.7% of the performance decline observed in the placebo group in a run-to-exhaustion model. The inv...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female adults aged 18 - 65 years.
• • Willing and able to provide written informed consent.
• • Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects.
• • Agreement to comply with the protocol and study restrictions.
• • Fluent in written and spoken English.
• • In good general health as judged by the Investigator based on medical history.
• • Willing to maintain daily exercise and diet habits throughout the 8 week study without making major lifestyle changes.
• • Ability to use a personal smartphone device and download the Chloe app by People Science
• Exclusion Criteria:
• • Currently pregnant, planning to become pregnant, or lactating during the next 12 weeks
• • Have a significant acute or chronic coexisting illness, disorder, or condition that contraindicates, in the Principal Investigator's judgment, entry to the study.
• • Currently taking immunosuppressive medications.
• • Is considered immunosuppressed for any reason.
• • Currently taking medications that could impair the integrity of the gut epithelia
• • Has symptoms or an illness, disorder, or cognition that impairs the integrity of the gut epithelia.
• • Current antibiotic use or planned oral antibiotic use over the course of the study.
• • Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study.